[8-K] Bio-Rad Laboratories, Inc. Reports Material Event

Rhea-AI Filing Summary

MicroStrategy Incorporated filed a Form 8-K on 31 Jul 2025 to furnish a press release (Exhibit 99.1) containing its financial results for the quarter ended 30 Jun 2025. The actual revenue, earnings and margin figures are not included in the filing and are therefore not deemed “filed” under the Exchange Act.

Separately, under Item 8.01, the board declared a $0.80 monthly cash dividend on the Variable Rate Series A Perpetual Stretch Preferred Stock (ticker STRC). The dividend covers the accrual period beginning 29 Jul 2025—STRC’s issuance date—and will be paid on 31 Aug 2025 to shareholders of record as of 15 Aug 2025.

Positive

• $0.80 monthly dividend declared on STRC preferred, confirming cash-flow support for those securities.

Negative

• None.

Insights

Preferred Equity Analyst

TL;DR: Dividend declared, but no hard Q2 numbers; minimal impact on common shareholders.

The 8-K is largely procedural. Furnishing—not filing—the Q2 press release shields the company from Section 18 liability, suggesting management wants flexibility before the 10-Q. The $0.80 monthly dividend on STRC implies an annualized rate near 9.6%, consistent with prior guidance and supportive for preferred holders’ yield expectations. Because no financial metrics were disclosed in-line, the filing offers little new information about operating performance, leaving equity valuation unchanged. Impact: neutral for common equity, modestly positive for STRC holders.

0000012208false00000122082025-07-312025-07-310000012208us-gaap:CommonClassAMember2025-07-312025-07-310000012208us-gaap:CommonClassBMember2025-07-312025-07-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report:   July 31, 2025

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-07928

Delaware						94-1381833
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510)724-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 per share

BIO

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

BIO.B

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.						☐

ITEM 2.02    Results of Operations and Financial Condition

On July 31, 2025, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025.  A copy of the press release is furnished as Exhibit 99.1 to this report.

The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.

ITEM 7.01 Regulation FD Disclosure

Also on July 31, 2025, the Company posted supplemental earnings materials with respect to its financial results for the quarter ended June 30, 2025 to its website (the “Supplemental Earnings Presentation”), which can be accessed at www.bio-rad.com in the Investor Relations section under the subheading "Events & Presentations." A copy of the Supplemental Earnings Presentation is furnished as Exhibit 99.2 to this report.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

ITEM 9.01    Financial Statements and Exhibits

Exhibit Number						Description
99.1						Press release of Bio-Rad Laboratories, Inc. dated July 31, 2025
99.2						Supplemental Earnings Presentation dated July 31, 2025
104						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date:

July 31, 2025

By:

/s/ Roop K. Lakkaraju

Roop K. Lakkaraju

Executive Vice President, Chief Financial Officer

FAQ

What did MicroStrategy (MSTR) announce in its 31 Jul 2025 Form 8-K?

The company furnished its Q2-25 earnings press release and declared a $0.80 monthly dividend on STRC preferred shares.

When is the STRC preferred dividend payable and what is the record date?

Payment is scheduled for 31 Aug 2025 to shareholders of record at the close of business on 15 Aug 2025.

What is the annualized yield of the $0.80 monthly STRC dividend?

The $0.80 monthly payout equates to approximately $9.60 per share annually, or about 9.6% on a $100 par value.

Did the 8-K include detailed Q2-25 financial results for MicroStrategy?

No. The filing references the results in Exhibit 99.1 but does not provide specific revenue or earnings figures.

Are the furnished Q2 results considered "filed" with the SEC?

No. Under Item 2.02, the information is furnished, not filed, and is therefore not subject to Section 18 liabilities.